Syndax_JPM2025_FINAL_

Syndax Corporate Presentation43rdAnnual J.P. Morgan Healthcare ConferenceJanuary 14, 2025Forward-lookingstatementsdisclosureThispresentationcontainsforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995.Wordssuchas"may,""will,""expect,""plan,""anticipate"andsimilarexpressions(aswellasotherwordsorexpressionsreferencingfutureevents,progress,timingorcircumstances)areintendedtoidentifyforward-lookingstatements.Allstatementsotherthanstatementsofhistoricalfactscontainedinthispresentation,includingstatementsregardingfutureoperations,financialresultsandthefinancialconditionofSyndaxPharmaceuticals,Inc.(“Syndax”orthe“Company”),includingfinancialposition,strategyandplans,theprogress,timing,clinicaldevelopmentandscopeofclinicaltrialsandthereportingofclinicaldataforSyndax’sproductcandidates,theprogressofregulatorysubmissionsandapprovalsandsubsequentcommercializationandthepotentialuseofSyndax’sproductcandidatestotreatvariouscancerindicationsandfibroticdiseases,andSy